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Abstract Acromegaly is a rare disease with a multifac-
eted clinical presentation. In 90–95% of patients with
acromegaly, the disease is caused by a growth hormone
(GH)-secreting pituitary adenoma with elevated GH levels
that ultimately induce excessive hepatic secretion of insu-
lin-like growth factor-1 (IGF-1). Somatostatin receptor
ligands (SRLs) are considered the standard medical choice
for the treatment of acromegaly, and normalization of GH
and IGF-1 is attainable with effective therapy. This review
aims to summarize the literature relative to SRL dose
escalation therapy in patients with acromegaly. A United
States National Library of Medicine PubMed search of
SRL’s was conducted using the following search terms:
((((LAR) OR ATG) OR octreotide) OR lanreotide Autogel)
AND acromegaly. Related articles in non peer-reviewed
journals were excluded. The rationale and beneﬁts of SRL
dose optimization therapy were investigated with emphasis
on describing the clinical recognition, treatment, and
management of patients with acromegaly. We found that
dose escalation could provide additional biochemical
control of acromegaly in patients who are inadequately
controlled with conventional starting doses of octreotide
LAR and lanreotide Autogel
. Furthermore, patients
should routinely have their GH and IGF-1 levels closely
monitored and their SRL dose increased or decreased
thereafter according to individual response.
Keywords Octreotide LAR  Lanreotide Autogel
 
Dose optimization  Acromegaly
Introduction
Acromegaly is a rare disease with a multifaceted clinical
presentation. The estimated prevalence of acromegaly
worldwide is considered to be around 60 cases per million
with approximately three new cases per million annually
[1, 2]. However, more recent European data pertinent to the
prevalence of clinically signiﬁcant pituitary adenomas
suggests that acromegaly could be more common [3]. In
most patients with acromegaly the disease is caused by a
growth hormone (GH)-secreting pituitary adenoma with
elevated GH levels that ultimately induce excessive hepatic
secretion of insulin-like growth factor-1 (IGF-1) [4]. The
pathologic effects of GH excess are acral overgrowth (i.e.,
macrognathia, enlargement of the facial bone structure, and
enlarged hands and feet); visceral overgrowth, including
macroglossia; and enlarged thyroid, liver, kidney, and
heart. Compared with healthy subjects, patients with
untreated acromegaly experience increased morbidity and
mortality [5], which is primarily due to cardiovascular
disease [6]. Despite long-term cure of GH excess, patients
are also likely to experience a decrease in quality of life
[7]. Control of GH/IGF-1 hypersecretion has been shown to
reduce mortality rates to levels similar to those in patients
without acromegaly [6, 8]. Somatostatin receptor ligands
(SRLs) are considered the medical treatment of choice for
acromegaly and normalization of GH and IGF-1 is attain-
able with effective therapy. However, some patients do not
achieve biochemical control with a standard dose of a SRL.
Recent treatment guidelines and clinical studies suggest
that SRL dose titration can improve control of GH and
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DOI 10.1007/s11102-010-0282-zIGF-1 in patients that have not achieved a full response to
an initial SRL dose [9, 10]. In this review we summarize
the literature relative to SRL dose escalation therapy in
patients with acromegaly. We also discuss clinical evi-
dence in support of optimal medical therapy that requires
individual SRL tailoring, including high-dose treatments in
acromegaly patients.
Literature search
A United States National Library of Medicine PubMed
search was conducted for the following: ((((LAR) OR
ATG) OR octreotide) OR lanreotide Autogel) AND acro-
megaly, through September 2010. Related articles in non
peer-reviewed journals were excluded. The studies selected
for review included those that evaluated the initial patient
response to SRL treatment followed by an attempt to
improve patient response with dose optimization therapy,
including either higher dose or higher frequency of doses.
Overall treatment goals
Treatment of acromegaly is complex and most cases
require a stepwise, multimodality approach to control dis-
ease progression. The treatment goals for patients with
acromegaly include: inhibiting GH hypersecretion, nor-
malizing IGF-1 levels, reducing tumor mass, and alleviat-
ing the comorbidities [4, 9, 11]. Adverse outcomes have
been linked to increases in both GH and IGF-1 levels,
therefore stringent biochemical criteria have been applied
over time (Fig. 1)[ 12]. Complete biochemical control is
deﬁned as serum GH levels of \1 lg/l if tested using a
sensitive immunoassay or B2.5 lg/l if measured by
radioimmunoassay, GH levels of \0.4 lg/l after oral
glucose tolerance test (OGTT), and normalization of serum
IGF-1 levels compared to age- and sex-matched controls
[9, 10, 12]. The algorithm depicted in Fig. 2 represents the
current surgical and pharmacological options for the
diagnosis and treatment of acromegaly [9, 10]. Surgery is
effective as a ﬁrst-line treatment option for biochemical
control in approximately 80% of patients with microade-
noma [13–16]. Surgical treatment has the dual advantage of
rapidly improving symptoms caused by mass effect of the
tumor and signiﬁcantly reducing or normalizing GH/IGF-1
concentrations. Cure rates with larger and invasive tumors
are much smaller (50–60%) and the initiation of medical
therapy is recommended after surgery.
Somatostatin receptor ligands
In the last two decades, the development of highly speciﬁc
and selective synthetic somatostatin analogs that act as
ligands for the somatostatin receptor has led to signiﬁcant
progress in the treatment of acromegaly [17]. The leading
consensus guidelines for the treatment of acromegaly
maintain that SRLs, have emerged as the primary medical
therapy for controlling GH excess [18]. In addition, recent
results show that octreotide LAR can be a viable option for
the ﬁrst-line treatment of acromegaly as long-term treat-
ment with octreotide LAR does not signiﬁcantly differ
from surgery [19].
SRLs act at four levels to target abnormal GH secretion:
(1) suppression of GH secretion from the pituitary and
from GH-secreting adenomas, (2) decrease in binding to
hepatocyte GH receptors, (3) inhibition of hepatic IGF-1
synthesis, and (4) control of tumor growth [20]. Two
commercially available SRLs; octreotide LAR and lanre-
otide Autogel (ATG), have unique therapeutic effects
based on their different pharmacokinetic properties and
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123patterns of receptor afﬁnity. They each bind with varying
afﬁnity to the ﬁve somatostatin receptors (SSTRs) but both
bind preferentially to SSTR2 [21]. Resistance to SRL
therapy that is reported in some patients could be
explained, in part, by variable tumor expression and/or
decreased density of SSTR2 expression [22]. Currently,
there are other SRLs in clinical trials: the next generation
SRL, pasireotide (SOM230) is in phase 3 development and
a chimeric molecule, dopamine-SRL (dopastatin), is in
phase 2 development. Pasireotide is a novel multi-ligand
SRL with a unique structure, potent in vitro and in vivo
inhibitory effects on GH and IGF-1 release, and a high
binding afﬁnity to SSTR1, -2, -3, and -5 with up to a 40-
fold greater afﬁnity for SSTR5 than octreotide. Based on
phase 2 results in patients with acromegaly [23], pasireo-
tide is considered a promising therapeutic candidate with
several potential advantages over currently used SRLs in
GH-secreting adenomas that are either unresponsive or
resistant to current therapy [24].
The use of octreotide LAR for the treatment of patients
with acromegaly is supported by more than 20 years of
clinical research and experience [18]. The usual starting
dose for octreotide LAR is 20 mg with titration down to
10 mg or up to 30, 40 or 60 mg, based on the need to attain
biochemical control [25]. An initial study that evaluated
the efﬁcacy, tolerability, and pharmacokinetics of octreo-
tide LAR determined that a 10 mg dose was considerably
less effective than a 20 or 30 mg dose, and that an interval
of 60 days between injections seemed too long. Much
better control was achieved by delivering either a 20 or
30 mg dose every 28 or 42 days [26, 27].
A more recent development has been the introduction
of lanreotide ATG, a supersaturated aqueous formulation
in a preﬁlled syringe that requires deep subcutaneous
administration every 28 days [28]. The usual starting
dose of lanreotide ATG is 90 mg every 4 weeks with
further titration up to 120 mg or down to 60 mg after
3 months based on the degree of biochemical response
[29]. Longer intervals between injections have also been
suggested [29, 30].
A large variability in the clinical response to SRL
therapy is reported in the published literature. Clinical
results of treatment with conventional doses of octreotide
LAR (20–30 mg/month) show that complete biochemical
control (GH levels B2.5 lg/l and IGF-1 normalization) is
achieved in between 38 and 85% and 33–75% of patients,
respectively [31–37]. Lanreotide slow release (SR) at
conventional doses reduced plasma GH levels (\5 lg/l) in
54–68% of patients and normalized IGF-1 levels in
35–63% of patients [38, 39].
Additionally, the selection of patients who are expec-
ted to beneﬁt from treatment with SRLs [31] and the
optimal time to evaluate their response has changed over
time. Consequently, Cozzi et al. suggested that clinicians
evaluate patients 3–6 months after starting octreotide
LAR therapy rather than discontinuing treatment at
3 months since the change in GH and IGF-1 levels after
6 months of treatment can predict the patients’ response
to treatment [34]. Elevated baseline GH and IGF-1 levels
were not found to be accurate predictors of patient
response to SRL therapy and thus SRL treatment should
be also considered in such patients [34]. Most importantly,
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123there is an ever-increasing quantity of clinical evidence
that supports dose optimization with SRLs [40–42].
Recently updated guidelines state that patients should be
continually monitored and, if necessary, recommend that
dose optimization of SRL therapy should be performed at
3-month intervals based on the patient response [10, 43].
Collectively, these reports demonstrate that dose escala-
tion, including high-dose treatment, improves the symp-
toms and comorbidities in patients with acromegaly
without signiﬁcant change to the safety and adverse
events observed with conventional doses.
In patients with different treatment histories (mixed
populations), the efﬁcacy of octreotide LAR appears to
be generally similar to that of lanreotide ATG and
slightly better than that of lanreotide SR, according to
data from switching or crossover studies [44, 45].
Patients who had previously responded to treatment with
subcutaneous octreotide showed the greatest response. A
number of studies have been carried out to compare the
biochemical efﬁcacy of octreotide LAR and lanreotide
SR. However, these studies are almost exclusively open-
label, prospective studies with varying inclusion criteria.
A meta-analysis of the results from 44 available trials
that compared the efﬁcacy of octreotide LAR and lan-
reotide SR determined that the biochemical efﬁcacy of
octreotide LAR is greater than that of lanreotide SR
among subjects not selected for prior SRL responsive-
ness [46]. Other reviews of SRL therapy suggest that
lanreotide ATG and octreotide LAR are of equivalent
efﬁcacy; however, a robust analysis is not possible given
the limited power of the studies reviewed [44, 45]. The
efﬁcacy of SRLs should continue to be evaluated in
prospective, randomized trials evaluating efﬁcacy with
respect to GH control and tumor shrinkage.
Rationale and beneﬁts of SRL dose optimization
therapy
In patients with insufﬁcient biochemical response to a
speciﬁc SRL dose, both dose optimization and/or addition
of another therapy have been suggested [36, 44]. Treatment
guidelines recommend evaluation of biochemical control
and dose titration of the SRL every 3 months if appropriate
[43]. Combination therapy has inherent advantages, but it
is outside the focus of the present review.
Control of GH and IGF-1 diminishes and reduces mor-
tality to expected levels [8, 47, 48]. In select cases such as
large residual tumors with cavernous sinus invasion, ele-
vated baseline GH and IGF-1, multiple co-morbidities, and
longer duration of the disease, our approach is to start
treatment with octreotide LAR 30 mg or lanreotide ATG
120 mg every 28 days for 3 months. Subsequent dose
titration, either up or down, is based on the biochemical
results and the patient’s clinical response. If the patient’s
responseisinadequate, theoctreotideLARdoseisincreased
to 40 mg/month. This treatment approach is similar to other
established endocrinology centers [40]. Presently, our
experience at the Northwest Pituitary Center at Oregon
Health & Science University with high-dose SRL treatment
is limited to octreotide LAR. If the patient does not respond
to the higher dose we proceed to combination therapy
without discontinuation of SRLs, albeit at lower doses.
A selection of recent clinical reports describing the
beneﬁt of dose-optimization therapy with octreotide LAR
and lanreotide ATG are summarized in Tables 1 and 2,
respectively. In one of the earliest studies, Lancranjan et al.
demonstrated that dose escalation with octreotide LAR
from 20 to 30 mg/month in 22 patients reduced the mean
GH level by 26% at 48 weeks [36]. In a 2-year study of 36
Table 1 Beneﬁts of octreotide LAR dose optimization therapy
Reference Highest dose
(mg/month)
Patients on this
dose (%)
Total number
of patients (n)
Duration of
treatment
Patients with GH
B2.5 lg/l (%)
Patients with
normalized IGF-1 (%)
Lancranjan et al. [36] 30 15 151 12 months 69.8 65.8
Colao et al. [32]3 0
40
33
19
36 12–24 months 69.4 61.1
Cozzi et al. [34]3 0
40
38
4
110 4 years 72 75
Colao et al. [51]3 0
40
27
30
56 24 months 86 84
Colao et al. [19] 30 82 (of safety
population)
40 (protocol
completers)
50 weeks 27.5 (Patients achieving both GH and IGF-1
control)
Giustina et al. [56]6 0
30 (every 3 weeks)
11
15
26 24 weeks 27*
0
36
0
*G H\2 lg/l
Pituitary (2011) 14:184–193 187
123patients with acromegaly by Colao et al., 43% of patients
achieved control of both GH and IGF-1 levels when the
starting dose of octreotide LAR (20 mg/month) was
increased to 30 mg/month and an additional 20% achieved
biochemical control upon an increase to 40 mg/month [32].
Another trial conducted on 110 patients treated for up to
54 months with octreotide LAR reported that dose opti-
mization may provide a signiﬁcant beneﬁt for patients with
acromegaly [34]. Dose titration was based on IGF-1 nor-
malization and increasing the starting dose of octreotide
L A Rf r o m2 0t o3 0m g / m o n t hs i g n i ﬁ c a n t l yd e c r e a s e dI G F - 1 .
At the end of the study 38% of patients (n = 42) were
being treated with octreotide LAR 30 mg/month, 4% were
treated with 40 mg/month while 33% continued on the
starting dose (20 mg/month).
The efﬁcacy of titrated versus ﬁxed doses of lanreotide
ATG has been compared and the same improvement in
patient outcome with dose optimization was reported. After
1 year of treatment, the mean plasma GH and IGF-1 con-
centrations in 130 patients were signiﬁcantly lower for
titrated lanreotide ATG than with ﬁxed doses of lanreotide
ATG (Fig. 3)[ 29]. The efﬁcacy of lanreotide ATG in
decreasing GH and IGF-1 has also been conﬁrmed in
patients previously treated with octreotide LAR. After a
washout period, patients were switched to lanreotide ATG
(120 mg) and the time between doses was adjusted based
on the GH and IGF-1 response. Based on the need for
additional treatment, the frequency was increased in 12/23
patients to every 4 weeks, 4/23 patients remained on the
original starting dose every 6 weeks, and 6/23 patients
were reduced to treatment every 8 weeks. At the end of the
study, the number of patients that achieved GH\2.5 lg/l
and normalized IGF-1 was 62 and 43% patients, respec-
tively [30]. In another study, 63 patients with acromegaly
were treated with lanreotide ATG (90 mg/4 weeks) with
the dose adjusted to achieve normalized, age- and sex-
matched, levels of IGF-1. By the end of the study 73% of
patients required an increase to 120 mg [49]. A randomized
placebo-controlled study in an unselected population of 99
patients published in 2010 showed that lanreotide ATG was
effective in controlling both GH and IGF-1 hypersecretion:
54% of patients had normalized IGF-1 and 38% achieved a
combined criterion of GH level B2.5 lg/l and normalized
IGF-1. Unsurprisingly, at the end of the open-label phase,
65/99 patients were on the highest dose (120 mg every
4 weeks) [50].
Use of SRLs as primary therapy
Of late, much interest has surrounded the use of SRLs in
primary therapy or preoperative treatment to improve sur-
gical outcomes, and dose optimization therapy has also
proven beneﬁcial in ﬁrst-line treatment of patients with
acromegaly. A 2-year dose-escalation study by Colao et al.
using octreotide LAR as the ﬁrst-line therapy in 56 patients
with acromegaly demonstrated that 32/56 (57%) required a
Table 2 Beneﬁts of lanreotide ATG dose optimization therapy
Reference Highest dose
(mg/month)
Patients on this
dose (%)
Total number
of patients (n)
Duration of
treatment
Patients with GH
B2.5 lg/l (%)
Patients with
normalized IGF-1 (%)
Caron et al. [29] 120 mg 48 130 1 year 68 50
Ronchi et al. [30] 120 mg/8 week 27 6 42 weeks 62 43
120 mg/6 week 18 4 36 weeks
120 mg/4 week 55 12 34 weeks
Attanasio et al. [58] 180 mg 4 26 1 year 42 54
Chanson et al. [49] 120 mg 73 63 48 weeks 85 43
Melmed et al. [65] 120 mg 65 99 52 weeks 38 54
Change in mean GH and IGF-1 concentration of
titrated versus fixed dose of lanreotide ATG (%)
0 5 10 15 20
IGF-1
GH
Fig. 3 Percent reduction of GH and IGF-1 concentrations at
12 months in patients with acromegaly treated with titrated versus
ﬁxed doses of lanreotide ATG
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123dose increase from the starting dose of 20 mg/month
(group A) to either 30 mg/month (group B) or 40 mg/
month (group C) to achieve control of GH and IGF-1
levels. At 24 months, control of GH and IGF-1 was
achieved in 24/56 (42.9%) patients treated with octreotide
LAR 20 mg/month, 15/56 (26.8%) patients receiving
30 mg/month and 6/56 (10.7%) patients who had their
octreotide LAR dose increased to 40 mg/month (Fig. 4)
[51]. Overall, dose optimization clearly beneﬁted the
patients in this study such that 86% of patients achieved
GH levels of B2.5 lg/l and 84% achieved normalized IGF-1
levels. More importantly, a third of the patients that were
not controlled on a lower dose achieved remission after
increasing their dose. A different approach was tried in
another 12-month, open-label, prospective study [52].
Twenty-six newly diagnosed patients with acromegaly
were treated with lanreotide ATG (120 mg/4 weeks). The
interval between injections was increased to every
6–8 weeks in patients that achieved biochemical control
(GH B2.5 lg/l and normalized IGF-1). After 12 months,
biochemical control was achieved in 14/26 (54%) patients
with nine patients still receiving the lanreotide dose every
4 weeks, while the dosage was delayed to every 6 weeks in
eight patients and every 8 weeks in nine patients. This
dosing regimen also induced at least 25% tumor shrinkage
in 77% of the patients in the study.
Tumor volume reduction
There is clear evidence that SRL treatment induces tumor
volume reduction in the majority of patients [53]. How-
ever, deﬁnitions of signiﬁcant tumor reduction and optimal
measurement are still under debate. Unsurprisingly, higher
doses of SRLs were found to be more efﬁcacious. Colao
et al. in 2007 demonstrated that mean pituitary tumor
volume was decreased by 68% after 24 months in patients
treated with octreotide LAR at doses of up to 40 mg/month
[51]. Furthermore, higher tumor volume reduction was
detected at 24 months in patients who had their octreotide
LAR dose increased to 40 mg/month (Fig. 5)[ 51]. These
results led to a hypothesis and possible advantage of using
initial high doses of octreotide LAR for macroadenomas
[40]. In a 5-year study of patients with acromegaly, tumor
shrinkage was 75 and 78% in the octreotide LAR (30-
40 mg, every 28 days) and lanreotide ATG (60-120 mg,
every 21–28 days) groups, respectively [54]. A systematic
review of 22 studies published in 2010 found that 33% of
patients experienced a variable degree of tumor volume
reduction (from 10 to 77%) during lanreotide SR or ATG
treatment [55]. As expected, tumor reduction was more
frequently observed in patients that were naı ¨ve to SRLs and
had macroadenomas. No obvious correlation between
biochemical response and tumor volume reduction has
been noted in patients treated with lanreotide ATG. The
observation that dose optimization can increase the number
of patients achieving biochemical control [19] has been
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123conﬁrmed in another recent study. A randomized, 50-week
trial designed to determine the beneﬁt of ﬁrst-line octreo-
tide LAR treatment versus surgery demonstrated that 42/51
(82%) patients initially randomized to octreotide LAR
20 mg required a dose increase to 30 mg during the study
in order to achieve biochemical control. In addition to
biochemical control, at week 24, the mean tumor volume
for the octreotide LAR-treated group decreased by 21%
from baseline, and by 35% by week 48. Seventy-three
percent of octreotide LAR-treated patients had signiﬁcant
([20%) tumor shrinkage over the 48-week study period.
Efﬁcacy of ‘‘high-dose/high-frequency’’ SRLs
More recently, in patients inadequately controlled on
conventional doses of octreotide LAR (20–30 mg/month),
both higher dose ([40 mg/month) or higher frequency
administration (30 mg every 3 weeks) has been tested to
determine if disease control can be improved [56]. In a
prospective, open-label multicenter study, 28 patients who
were responsive to conventional-dose SRL therapy but did
not achieve biochemical control were treated with either
high-dose (60 mg/month) or high-frequency octreotide
LAR. After 24 weeks of treatment, 27% (3/11) of patients
treated with high-dose octreotide LAR achieved control of
GH (\2 lg/l) and 36% (4/11) achieved normalization of
IGF-1 [56]. More importantly, in the high-dose group, 90%
of patients had noticeable decreases in IGF-1 levels
(Fig. 6)[ 56].
Experience with high-dose ([120 mg/month) or high-
frequency (every 3 weeks) lanreotide ATG treatment is
limited to case reports. In two patients with acromegaly
who were not suitable for surgery, Wuster et al. increased
the dose of lanreotide ATG sequentially up to 180 mg
every 3–4 weeks for 3–6 months if the biochemical
response of the patient was unsatisfactory [57]. Tumor
volume reduction was observed with no drug-related
adverse events. Clinical use of high-dose lanreotide ATG
therapy was reported for an additional six patients who
were titrated up to 180 mg/month in two separate clinical
studies [58, 59].
Safety and tolerability of SRLs is maintained at higher
doses
SRLs are well tolerated in most patients and treatment
discontinuations due to adverse events are generally related
to transient gastrointestinal (GI) disturbances [43]. The
most commonly reported adverse events are injection-site
discomfort and erythema, GI disturbances (such as diar-
rhea, abdominal pain, nausea and vomiting), biliary sludge
or gallstones, and abnormal glucose metabolism [60].
However, most adverse events are transient and of mild-to-
moderate intensity. SRL treatment can create conditions
that favor precipitation of microcrystals and stone forma-
tion; however, gallbladder sludge and gallstones are usu-
ally asymptomatic and do not require surgery [61], which
was conﬁrmed using ultrasound surveillance of patients
with acromegaly treated with octreotide LAR [36]. Glucose
metabolism in patients with acromegaly treated with SRLs
is very complex. Excess of GH in acromegaly is frequently
associated with insulin resistance [4]. SRLs signiﬁcantly
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123improve GH thus increasing insulin sensitivity, but exper-
imental and clinical evidence suggests that this treatment
could have negative effects on b-cell function [62].
Hypoglycemia has also been reported. A recent meta-
analysis of 31 studies in patients treated with SRLs showed
a statistically signiﬁcant decrease in fasting plasma insulin,
but without any signiﬁcant change in fasting plasma glu-
cose [63]. Clinical results from studies of patients with
acromegaly treated with doses of octreotide LAR up to
60 mg/month show a similar safety proﬁle to that reported
with conventional treatment (20–30 mg/month) with
octreotide LAR. The adverse events reported from patients
in the dose-optimization studies discussed above were very
similar to conventional therapy with octreotide LAR and
report mild adverse events mostly involving the gastroin-
testinal tract [32, 36, 51, 64]. Some studies reported non-
signiﬁcant increases in gallstones or gallbladder sludge [32,
51, 56]. A Japanese study evaluating octreotide LAR
40 mg/month for a duration of 40 months in patients with
acromegaly reported that treatment was safe and did not
effect glycosylated hemoglobin (HbA1c) levels negatively
[64]. Giustina et al. 2009 demonstrated no dose–response
effect in terms of adverse events. A slight decrease in
median HbA1c was observed in the high-dose group
(60 mg/month) but not in the high-frequency group (30 mg
every 3 weeks) [56]. Studies of patients treated with doses
of lanreotide ATG up to 120 mg also report mainly GI
adverse events. The case reports of patients treated with
lanreotide ATG doses C120 mg every 4 weeks revealed no
unexpected adverse events [57].
Conclusions
Treatment approach should be individualized to take into
consideration a patient’s tumor size and location, symp-
toms, comorbid conditions, and preferences. Novel medical
treatments with different therapeutic regimens using SRLs
are gaining importance while a second wave of more
effective drugs is in development. Careful monitoring of
the medical therapy of acromegaly, both primary and
adjuvant, plays an important role in successfully control-
ling the signs and symptoms of the disease. The current
review of published clinical studies demonstrates that dose
escalation could provide additional biochemical control of
acromegaly in patients who are inadequately controlled
with conventional starting doses of octreotide LAR
(20 mg/month) and lanreotide ATG (90 mg every
4 weeks). Therefore, patients should routinely have their
GH and IGF-1 levels monitored and their SRL dose
increased or decreased thereafter according to their indi-
vidual response. Furthermore, multiple studies have now
proven that higher doses of octreotide LAR could provide
additional efﬁcacy without signiﬁcantly changing the
safety and adverse events seen with conventional doses.
The potential long-term use of SRLs at doses higher than
the maximum labeled dose should still be evaluated in
prospective, randomized trials with respect to GH control,
tumor shrinkage and safety proﬁle. It is important to also
consider the cost:beneﬁt ratio of high-dose compared with
combination therapy and the overall burden of uncontrolled
disease and complications.
Acknowledgments The author would like to thank Shirley Mc-
Cartney, Ph.D. and Tim Remus, Ph.D., for medical editorial assis-
tance with this manuscript. Partial ﬁnancial support (Tim Remus) for
editorial assistance was provided by Novartis Pharmaceuticals
Corporation.
Disclosures Dr. Fleseriu has received consultant fees from Novartis
Pharmaceuticals, Tercica, Inc., and Endo Pharmaceuticals, and is a
principal investigator in clinical trials sponsored by Novartis Phar-
maceuticals and Ipsen Pharma and co-investigator in a clinical trial
sponsored by Endo Pharmaceuticals.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Etxabe J, Gaztambide S, Latorre P, Vazquez JA (1993) Acro-
megaly:anepidemiologicalstudy.JEndocrinolInvest16:181–187
2. Holdaway IM, Rajasoorya C (1999) Epidemiology of acromeg-
aly. Pituitary 2:29–41
3. Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA,
Beckers A (2006) High prevalence of pituitary adenomas: a
cross-sectional study in the province of Liege, Belgium. J Clin
Endocrinol Metab 91:4769–4775
4. Melmed S (2006) Medical progress: acromegaly. N Engl J Med
355:2558–2573
5. Dekkers OM, Biermasz NR, Pereira AM, Romijn JA, Van-
denbroucke JP (2008) Mortality in acromegaly: a metaanalysis.
J Clin Endocrinol Metab 93:61–67
6. Holdaway IM, Rajasoorya RC, Gamble GD (2004) Factors
inﬂuencing mortality in acromegaly. J Clin Endocrinol Metab
89:667–674
7. Biermasz NR, Van Thiel SW, Pereira AM, Hoftijzer HC, van
Hemert AM, Smit JW, Romijn JA, Roelfsema F (2004)
Decreased quality of life in patients with acromegaly despite
long-term cure of growth hormone excess. J Clin Endocrinol
Metab 89:5369–5376
8. Holdaway IM, Bolland MJ, Gamble GD (2008) A meta-analysis
of the effect of lowering serum levels of GH and IGF-I on
mortality in acromegaly. Eur J Endocrinol 159:89–95
9. AACE Acromegaly Guidelines Task Force (2004) AACE medi-
cal guidelines for clinical practice for the diagnosis and treatment
of acromegaly. Endocr Pract 10:213–225
10. Melmed S, Colao A, Barkan A, Molitch M, Grossman AB,
Kleinberg D, Clemmons D, Chanson P, Laws E, Schlechte J,
Vance ML, Ho K, Giustina A (2009) Guidelines for acromegaly
management: an update. J Clin Endocrinol Metab 94:1509–1517
Pituitary (2011) 14:184–193 191
12311. Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L,
Ho K, Veldhuis J, Wass J, von Werder K, Melmed S (2000)
Criteria for cure of acromegaly: a consensus statement. J Clin
Endocrinol Metab 85:526–529
12. Giustina A, Chanson P, Bronstein MD, Klibanski A, Lamberts S,
Casanueva FF, Trainer P, Ghigo E, Ho K, Melmed S (2010) A
consensus on criteria for cure of acromegaly. J Clin Endocrinol
Metab 95:3141–3148
13. Beauregard C, Truong U, Hardy J, Serri O (2003) Long-term
outcome and mortality after transsphenoidal adenomectomy for
acromegaly. Clin Endocrinol (Oxf) 58:86–91
14. De P, Rees DA, Davies N, John R, Neal J, Mills RG, Vaﬁdis J,
Davies JS, Scanlon MF (2003) Transsphenoidal surgery for
acromegaly in wales: results based on stringent criteria of
remission. J Clin Endocrinol Metab 88:3567–3572
15. Nomikos P, Buchfelder M, Fahlbusch R (2005) The outcome of
surgery in 668 patients with acromegaly using current criteria of
biochemical ‘cure’. Eur J Endocrinol 152:379–387
16. Shimon I, Cohen ZR, Ram Z, Hadani M (2001) Transsphenoidal
surgery for acromegaly: endocrinological follow-up of 98
patients. Neurosurgery 48:1239–1243
17. Fleseriu M, Delashaw JB, Cook DM (2010) Acromegaly: a
review of current medical therapy and new drugs on the horizon.
Neurosurg Focus 29:E15
18. Anthony L, Freda PU (2009) From somatostatin to octreotide
LAR: evolution of a somatostatin analogue. Curr Med Res Opin
25:2989–2999
19. Colao A, Cappabianca P, Caron P, De Menism E, Farrall AJ,
Gadelha MR, Hmissi A, Rees A, Reincke M, Safari M, T’Sjoen
G, Bouterfa H, Cuneo RC (2009) Octreotide LAR vs. surgery in
newly diagnosed patients with acromegaly: a randomized, open-
label, multicentre study. Clin Endocrinol (Oxf) 70:757–768
20. Murray RD, Kim K, Ren S-G, Chelly M, Umehara Y, Melmed S
(2004) Central and peripheral actions of somatostatin on the
growth hormone-IGF-I axis. J Clin Invest 114:349–356
21. Schmid HA (2008) Pasireotide (SOM230): development, mech-
anism of action and potential applications. Mol Cell Endocrinol
286:69–74
22. Casarini AP, Jallad RS, Pinto EM, Soares IC, Nonogaki S,
Giannella-Neto D, Musolino NR, Alves VA, Bronstein MD
(2009) Acromegaly: correlation between expression of somato-
statin receptor subtypes and response to octreotide-lar treatment.
Pituitary 12:297–303
23. Petersenn S, Schopohl J, Barkan A, Mohideen P, Colao A, Abs R,
Buchelt A, Ho Y-Y, Hu K, Farrall AJ, Melmed S, Biller BM
(2010) Pasireotide (SOM230) demonstrates efﬁcacy and safety in
patients with acromegaly: a randomized, multicenter, Phase II
trial. J Clin Endocrinol Metab 95:2781–2789
24. Wilson C (2010) Pharmacotherapy: Pasireotide shows promise
for the treatment of acromegaly. Nat Rev Endocrinol 6:417
25. Colao A, Faggiano A, Pivonello R (2010) Somatostatin ana-
logues: treatment of pituitary and neuroendocrine tumors. Prog
Brain Res 182:281–294
26. Flogstad AK, Halse J, Bakke S, Lancranjan I, Marbach P, Bruns
C, Jervell J (1997) Sandostatin LAR in acromegalic patients:
long-term treatment. J Clin Endocrinol Metab 82:23–28
27. Stewart PM, Kane KF, Stewart SE, Lancranjan I, Sheppard MC
(1995) Depot long-acting somatostatin analog (Sandostatin-LAR)
is an effective treatment for acromegaly. J Clin Endocrinol Metab
80:3267–3272
28. Caron P, Beckers A, Cullen DR, Goth MI, Gutt B, Laurberg P,
Pico AM, Valimaki M, Zgliczynski W (2002) Efﬁcacy of the new
long-acting formulation of lanreotide (lanreotide Autogel) in the
management of acromegaly. J Clin Endocrinol Metab 87:99–104
29. Caron P, Bex M, Cullen DR, Feldt-Rasmussen U, Pico Alfonso
AM, Pynka S, Racz K, Schopohl J, Tabarin A, Valimaki MJ
(2004) One-year follow-up of patients with acromegaly treated
with ﬁxed or titrated doses of lanreotide Autogel. Clin Endocrinol
(Oxf) 60:734–740
30. Ronchi CL, Boschetti M, Uberti EC, Mariotti S, Grottoli S, Loli
P, Lombardi G, Tamburrano G, Arvigo M, Angeletti G, Boscani
PF, Beck-Peccoz P, Arosio M (2007) Efﬁcacy of a slow-release
formulation of lanreotide (Autogel 120 mg) in patients with
acromegaly previously treated with octreotide long acting release
(LAR): an open, multicentre longitudinal study. Clin Endocrinol
(Oxf) 67:512–519
31. Bevan JS, Atkin SL, Atkinson AB, Bouloux P-M, Hanna F,
Harris PE, James RA, McConnell M, Roberts GA, Scanlon MF,
Stewart PM, Teasdale E, Turner HE, Wass JA, Wardlaw JM
(2002) Primary medical therapy for acromegaly: an open, pro-
spective, multicenter study of the effects of subcutaneous and
intramuscular slow-release octreotide on growth hormone, insu-
lin-like growth factor-I, and tumor size. J Clin Endocrinol Metab
87:4554–4563
32. Colao A, Ferone D, Marzullo P, Cappabianca P, Cirillo S, Boerlin
V, Lancranjan I, Lombardi G (2001) Long-term effects of depot
long-acting somatostatin analog octreotide on hormone levels and
tumor mass in acromegaly. J Clin Endocrinol Metab
86:2779–2786
33. Colao A, Pivonello R, Rosato F, Tita P, De Menis E, Barreca A,
Ferrara R, Mainini F, Arosio M, Lombardi G (2006) First-line
octreotide-LAR therapy induces tumor shrinkage and controls
hormone excess in patients with acromegaly: results from an
open, prospective, multicentre trial. Clin Endocrinol (Oxf)
64:342–351
34. Cozzi R, Attanasio R, Montini M, Pagani G, Lasio G, Lodrini S,
Barausse M, Albizzi M, Dallabonzana D, Pedroncelli AM (2003)
Four-year treatment with octreotide-long-acting repeatable in 110
acromegalic patients: predictive value of short-term results? J
Clin Endocrinol Metab 88:3090–3098
35. Cozzi R, Montini M, Attanasio R, Albizzi M, Lasio G, Lodrini
S, Doneda P, Cortesi L, Pagani G (2006) Primary treatment of
acromegaly with octreotide LAR: a long-term (up to 9 years)
prospective study of its efﬁcacy in the control of disease
activity and tumor shrinkage. J Clin Endocrinol Metab
91:1397–1403
36. Lancranjan I, Atkinson AB (1999) Results of a European multi-
centre study with Sandostatin
 LAR
 in acromegalic patients.
Sandostatin LAR group. Pituitary 1:105–114
37. Mercado M, Borges F, Bouterfa H, Chang T-C, Chervin A,
Farrall AJ, Patocs A, Petersenn S, Podoba J, Safari M, Wardlaw J
(2007) A prospective, multicentre study to investigate the efﬁ-
cacy, safety and tolerability of octreotide LAR
 (long-acting
repeatable octreotide) in the primary therapy of patients with
acromegaly. Clin Endocrinol (Oxf) 66:859–868
38. Caron P, Morange-Ramos I, Cogne M, Jaquet P (1997) Three
year follow-up of acromegalic patients treated with intramuscular
slow-release lanreotide. J Clin Endocrinol Metab 82:18–22
39. Giusti M, Ciccarelli E, Dallabonzana D, Delitala G, Faglia G,
Liuzzi A, Gussoni G, Giordano DG (1997) Clinical results of
long-term slow-release lanreotide treatment of acromegaly. Eur J
Clin Invest 27:277–284
40. Colao A, Lombardi G (2010) Dose optimization of somatostatin
analogues for acromegaly patients. J Endocrinol Invest
33:125–127
41. James RA, Gilroy J (2001) Dose and frequency titration of
somatostatin analogues in the treatment of acromegaly - an
injection of expediency? Clin Endocrinol (Oxf) 54:11–13
42. Jenkins PJ, Akker S, Chew SL, Besser GM, Monson JP, Gross-
man AB (2000) Optimal dosage interval for depot somatostatin
analogue therapy in acromegaly requires individual titration. Clin
Endocrinol (Oxf) 53:719–724
192 Pituitary (2011) 14:184–193
12343. Melmed S, Casanueva F, Cavagnini F, Chanson P, Frohman LA,
Gaillard R, Ghigo E, Ho K, Jaquet P, Kleinberg D, Lamberts S,
Laws E, Lombardi G, Sheppard MC, Thorner M, Vance ML,
Wass JA, Giustina A (2005) Consensus statement: medical
management of acromegaly. Eur J Endocrinol 153:737–740
44. Feelders RA, Hoﬂand LJ, van Aken MO, Neggers SJ, Lamberts
SW, de Herder WW, van der Lely A-J (2009) Medical therapy of
acromegaly: efﬁcacy and safety of somatostatin analogues. Drugs
69:2207–2226
45. Murray RD, Melmed S (2008) A critical analysis of clinically
available somatostatin analog formulations for therapy of acro-
megaly. J Clin Endocrinol Metab 93:2957–2968
46. Freda PU, Katznelson L, van der Lely AJ, Reyes CM, Zhao S,
Rabinowitz D (2005) Long-acting somatostatin analog therapy of
acromegaly: a meta-analysis. J Clin Endocrinol Metab
90:4465–4473
47. Ayuk J, Sheppard MC (2006) Growth hormone and its disorders.
Postgrad Med J 82:24–30
48. Ayuk J, Sheppard MC (2008) Does acromegaly enhance mor-
tality? Rev Endocr Metab Disord 9:33–39
49. Chanson P, Borson-Chazot F, Kuhn J-M, Blumberg J, Maisonobe
P, Delemer B (2008) Control of IGF-I levels with titrated dosing
of lanreotide Autogel over 48 weeks in patients with acromegaly.
Clin Endocrinol (Oxf) 69:299–305
50. Melmed S, Cook D, Schopohl J, Goth MI, Lam KS, Marek J
(2010) Rapid and sustained reduction of serum growth hormone
and insulin-like growth factor-1 in patients with acromegaly
receiving lanreotide Autogel((R)) therapy: a randomized, pla-
cebo-controlled, multicenter study with a 52 week open exten-
sion. Pituitary 13:18–28
51. Colao A, Pivonello R, Auriemma RS, Galdiero M, Savastano S,
Lombardi G (2007) Beneﬁcial effect of dose escalation of
Octreotide-LAR as ﬁrst-line therapy in patients with acromegaly.
Eur J Endocrinol 157:579–587
52. Colao A,AuriemmaRS,ReboraA,GaldieroM,ResminiE,Minuto
F, Lombardi G, Pivonello R, Ferone D (2009) Signiﬁcant tumour
shrinkage after12 monthsofLanreotide Autogel-120 mgtreatment
given ﬁrst-line in acromegaly. Clin Endocrinol (Oxf) 71:237–245
53. Amato G, Mazziotti G, Rotondi M, Iorio S, Doga M, Sorvillo F,
Manganella G, Di Salle F, Giustina A, Carella C (2002) Long-
term effects of lanreotide SR and octreotide LAR
 on tumour
shrinkage and GH hypersecretion in patients with previously
untreated acromegaly. Clin Endocrinol (Oxf) 56:65–71
54. Colao A, Auriemma RS, Galdiero M, Lombardi G, Pivonello R
(2009) Effects of initial therapy for ﬁve years with somatostatin
analogs for acromegaly on growth hormone and insulin-like
growth factor-I levels, tumor shrinkage, and cardiovascular dis-
ease: a prospective study. J Clin Endocrinol Metab 94:3746–3756
55. Mazziotti G, Giustina A (2010) Effects of lanreotide SR and
Autogel on tumor mass in patients with acromegaly: a systematic
review. Pituitary 13:60–67
56. Giustina A, Bonadonna S, Bugari G, Colao A, Cozzi R, Cannavo
S, De Marinis L, Degli Uberti E, Bogazzi F, Mazziotti G, Minuto
F, Montini M, Ghigo E (2009) High-dose intramuscular octreo-
tide in patients with acromegaly inadequately controlled on
conventional somatostatin analogue therapy: a randomised con-
trolled trial. Eur J Endocrinol 161:331–338
57. Wuster C, Both S, Cordes U, Omran W, Reisch R (2010) Primary
treatment of acromegaly with high-dose lanreotide: a case series.
J Med Case Reports 4:85
58. Attanasio R, Lanzi R, Losa M, Valentini F, Grimaldi F, De ME,
Davi MV, Battista C, Castello R, Cremonini N, Razzore P, Ro-
sato F, Montini M, Cozzi R (2008) Effects of lanreotide Autogel
on growth hormone, insulinlike growth factor 1, and tumor size in
acromegaly: a 1-year prospective multicenter study. Endocr Pract
14:846–855
59. Toledano Y, Rot L, Greenman Y, Orlovsky S, Pauker Y, Olc-
hovsky D, Eliash A, Bardicef O, Makhoul O, Tsvetov G, Ger-
shinsky M, Cohen-Ouaqnine O, Ness-Abramof R, Adnan Z, Ilany
J, Guttmann H, Sapir M, Benbassat C, Shimon I (2009) Efﬁcacy
of long-term lanreotide treatment in patients with acromegaly.
Pituitary 12:285–293
60. Freda PU (2002) Somatostatin analogs in acromegaly. J Clin
Endocrinol Metab 87:3013–3018
61. Cozzi R, Attanasio R (2007) Octreotide for acromegaly. Expert
Rev Endocrinol Metab 2:129–145
62. Baldelli R, Battista C, Leonetti F, Ghiggi M-R, Ribaudo M-C,
Paoloni A, D’Amico E, Ferretti E, Baratta R, Liuzzi A, Trischitta
V, Tamburrano G (2003) Glucose homeostasis in acromegaly:
effects of long-acting somatostatin analogues treatment. Clin
Endocrinol (Oxf) 59:492–499
63. Mazziotti G, Floriani I, Bonadonna S, Torri V, Chanson P,
Giustina A (2009) Effects of somatostatin analogs on glucose
homeostasis: a metaanalysis of acromegaly studies. J Clin
Endocrinol Metab 94:1500–1508
64. Yetkin DO, Boysan SN, Tiryakioglu O, Yalin AS, Kadioglu P
(2007) Forty-month follow-up of persistent and difﬁcultly con-
trolled acromegalic patients treated with depot long acting
somatostatin analog octreotide. Endocr J 54:459–464
65. Melmed S, Cook D, Schopohl J, Goth MI, Lam KS, Marek J
(2010) Rapid and sustained reduction of serum growth hormone
and insulin-like growth factor-1 in patients with acromegaly
receiving lanreotide Autogel((R)) therapy: a randomized, pla-
cebo-controlled, multicenter study with a 52 week open exten-
sion. Pituitary 13:18–28
Pituitary (2011) 14:184–193 193
123